Valeant to buy Obagi Medical for about $344 mln
March 20 (Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc said it would buy Obagi Medical Products Inc for about $344 million to boost its dermatology and aesthetics portfolio.
The deal, at $19.75 per share in cash, is at a 28 percent premium to Obagi's Tuesday closing price.
Obagi's board has unanimously approved the deal, Valeant said in a statement.
- Malaysian plane presumed crashed; questions over false IDs |
- China draws 'red line' on North Korea, says won't allow war on peninsula
- Warning shots fired to turn monitors back from Crimea |
- Malaysian plane crashed off Vietnam coast: state media